Response to Is radiotherapy the best option for treating hepatocellular carcinoma with PVTT?
Liver Int
.
2017 Feb;37(2):308-309.
doi: 10.1111/liv.13278.
Authors
Jung Ho Im
1
,
Sang Min Yoon
2
,
Hee Chul Park
3
4
,
Jong Hoon Kim
2
,
Jeong Il Yu
3
4
,
Tae Hyun Kim
5
,
Jun Won Kim
6
,
Taek-Keun Nam
7
,
Kyubo Kim
8
,
Hong Seok Jang
9
,
Jin Hee Kim
10
,
Mi-Sook Kim
11
,
Won Sup Yoon
12
,
Inkyung Jung
13
,
Jinsil Seong
1
Affiliations
1
Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
2
Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
4
Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Korea.
5
Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
6
Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
7
Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.
8
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
9
Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
10
Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
11
Department of Radiation Oncology, Korea Institute Radiological & Medical Sciences, Seoul, Korea.
12
Department of Radiation Oncology, Ansan Hospital, Korea University Medical Center, Ansan, Korea.
13
Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea.
PMID:
28070983
DOI:
10.1111/liv.13278
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Carcinoma, Hepatocellular*
Chemoembolization, Therapeutic
Humans
Liver Neoplasms*
Portal Vein